Clopidogrel-drug interactions

Journal of the American College of Cardiology

Volumn 57, Issue 11, 2011, Pages 1251-1263

  Bates, Eric R ^a   Lau, Wei C ^a   Angiolillo, Dominick J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

atorvastatin; clopidogrel; drug interactions; omeprazole; proton pump inhibitors; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450; DIAZEPAM; ESOMEPRAZOLE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LANSOPRAZOLE; OMEGA 3 FATTY ACID; OMEPRAZOLE; PANTOPRAZOLE; PHENPROCOUMON; PHENYTOIN; PLACEBO; PRAVASTATIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROSUVASTATIN; WARFARIN;

ARTICLE; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; CORONARY STENT; DEPRESSION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HEART INFARCTION; HUMAN; HYDROLYSIS; HYPERICUM PERFORATUM; LOADING DRUG DOSE; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79952378616     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.11.024     Document Type: Review

References (92)

1. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J Am Coll Cardiol 47 2006 e1 e121
2. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
3. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarctionexecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) J Am Coll Cardiol 44 2004 671 719
4. D.K. Badyal, and A.P. Dadhich Cytochrome P450 and drug interactions Indian J Pharmacol 33 2001 248 259 (Pubitemid 32842517)
5. W.C. Lau, L.A. Waskell, and P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37 (Pubitemid 36070929)
6. M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, and J. Boschat Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2006 2508 2509 (Pubitemid 44575451)
7. D.J. Angiolillo, and F. Alfonso Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol 50 2007 296 298
8. J.L. Ferreiro, and D.J. Angiolillo Antiplatelet therapy: clopidogrel plus PPIsa dangerous combination? Nat Rev Cardiol 6 2009 392 394
9. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
10. Z. Ding, S. Kim, R.T. Dorsam, J. Jin, and S.P. Kunapuli Inactivation of human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys 17 and Cys 270 Blood 101 2003 3908 3914 (Pubitemid 36857866)
11. W.C. Lau, P.A. Gurbel, and P.B. Watkins The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171 (Pubitemid 38114134)
12. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247 (Pubitemid 44497506)
13. A.E. Rtz Bravo, L. Tchambaz, and A. Krhenbühl-Melcher Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy Drug Saf 28 2005 263 275 (Pubitemid 40364892)
14. C.W. Howden Clinical pharmacology of omeprazole Clin Pharmacokinet 20 1991 38 49
15. P. Savi, J. Combalbert, and C. Gaich The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A Thromb Haemost 72 1994 313 317 (Pubitemid 24251300)
16. H.B. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker, and A. Mugge Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet functiona flow cytometry study Eur Heart J 24 2003 1744 1749 (Pubitemid 37236863)
17. W.C. Lau, C.J. Neer, A.R. Tait, D.G. Carville, K.E. Guyer, and E.R. Bates Higher doses of clopidogrel overcome the atorvastatin-clopidogrel drug-drug interaction (abstr) Circulation 112 2005 II-295
18. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59 (Pubitemid 36735258)
19. M. Piorkowski, U. Weikert, P.L. Schwimmbeck, P. Martus, H.P. Schultheiss, and U. Rauch ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin Thromb Haemost 92 2004 614 620 (Pubitemid 39248019)
20. V.L. Serebruany, M.G. Midei, and A.I. Malinin Absence of interaction between atorvastatin or other statins and clopidogrel Results from the Interaction Study Arch Intern Med 164 2004 2051 2057 (Pubitemid 39390564)
21. S.M. Smith, H.M. Judge, G. Peters, and R.F. Storey Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention Platelets 15 2004 465 474 (Pubitemid 39656854)
22. N.A. Farid, D.S. Small, and C.D. Payne Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects Pharmacotherapy 28 2008 1483 1494
23. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg, and M. Gawas Effects of statins on platelet inhibition by a high loading dose of clopidogrel Circulation 108 2003 2195 2197 (Pubitemid 37363034)
24. O. Gorchakova, N. von Beckerath, and M. Gawas Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting Eur Heart J 25 2004 1898 1902 (Pubitemid 39452606)
25. D. Trenk, W. Hochholzer, and D. Frundi Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement Thromb Haemost 99 2008 174 181
26. T. Geisler, C. Zürn, and M. Paterok Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy Eur Heart J 29 2008 1635 1643 (Pubitemid 351957543)
27. J.V. Mitsios, A.I. Papathanasiou, F.I. Rodis, M. Elisaf, J.A. Goudevenos, and A.D. Tselepis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338 (Pubitemid 38387816)
28. J.V. Mitsios, A.I. Papathanasiou, M. Elisaf, J.A. Goudevenos, and A.D. Tselepis The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes Platelets 16 2005 287 292 (Pubitemid 40943923)
29. R.E. Malmstrom, J. Ostergren, L. Jorgensen, and P. Hjemdahl Influence of statin treatment on platelet inhibition by clopidogrel: a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment J Intern Med 266; 2009 457 466
30. F. Mach, D. Senouf, and P. Fontana Not all statins interfere with clopidogrel during antiplatelet therapy Eur J Clin Invest 35 2005 476 481 (Pubitemid 41153201)
31. P. Vinholt, T.S. Poulsen, and L. Korsholm The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease Thromb Haemost 94 2005 438 443 (Pubitemid 41122501)
32. P.S.Windecker Wenaweser, and M. Billinger Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis Am J Cardiol 99 2007 353 356 (Pubitemid 46149554)
33. D. Dai, J. Tang, and R. Rose Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos J Pharmacol Exp Ther 299 2001 825 831 (Pubitemid 33104948)
34. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
35. T. Cuisset, C. Frere, and J. Quilici Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose The PACA (Proton Pump Inhibitors and clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
36. D. Sibbing, T. Morath, and J. Stegherr Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
37. H. Neubauer, A. Engelhardt, and J.C. Kruger Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study after coronary stenting J Cardiovasc Pharmacol 56 2010 91 97
38. J.L. Ferreiro, M. Ueno, and D. Capodanno Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study Circ Cardiovasc Interv 3 2010 436 441
39. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
40. C.S. Zuern, T. Geisler, N. Lutilsky, S. Winter, M. Schwab, and M. Gawaz Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy Thromb Res 125 2010 e51 e54
41. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantopraole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 2009 148.e15
42. D.S. Small, N.A. Farid, and C.D. Payne Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484 (Pubitemid 351389118)
43. D.J. Angiolillo, C.M. Gibson, and S. Cheng Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74
44. National Institutes of Health Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (SPICE) http://clinicaltrials.gov/ct2/show/NCT00930670 Accessed November 2, 2010
45. H.A. Wienbergen, A.K. Gitt, and R. Schiele Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288 (Pubitemid 36897711)
46. N.N. Wahab, J.L. Cox The ICON Investigators Does the use of atorvastatin with clopidogrel increase clinical adverse events after percutaneous coronary intervention (abstr)? Can J Cardiol 19 Suppl A 2003 231A 232A
47. S. Gulec, C. Ozdol, U. Rahimov, Y. Atmaca, D. Kumbasar, and C. Erol Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction J Invasive Cardiol 17 2005 589 593
48. D. Mukherjee, E. Kline-Rogers, J. Fang, K. Munir, and K.A. Eagle Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome Heart 91 2005 23 26 (Pubitemid 39664985)
49. M.J. Lim, F.A. Spencer, and J.M. Gore Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry Eur Heart J 26 2005 1063 1069 (Pubitemid 40839906)
50. J.M. Brophy, M.N. Babapulle, V. Costa, and S. Rinfret A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention Am Heart J 152 2006 263 269 (Pubitemid 44093398)
51. A. Blagojevic, J.A.C. Delaney, L.E. Levesque, N. Dendukuri, J.-F. Boivin, and J.M. Brophy Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study Pharmacoepidemiol Drug Saf 18 2009 362 369
52. J. Saw, S.R. Steinhubl, and P.B. Berger Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924 (Pubitemid 37048218)
53. J. Saw, D.M. Brennan, and S.R. Steinhubl Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 2007 291 295 (Pubitemid 47058889)
54. A. Lotfi, M.J. Schweiger, G.R. Giugliano, S.A. Murphy, and C.P. Cannon High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients: A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J 155 2008 954 958
55. E. Pezalla, D. Day, and I. Pulliadath Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors (letter) J Am Coll Cardiol 52 2008 1038 1039
56. M.A. Gaglia, R. Torguson, and N. Hanna Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes Am J Cardiol 105 2010 833 838
57. E. Gupta, D. Bansal, J. Sotos, and K. Olden Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention Dig Dis Sci 55 2010 1964 1968
58. J. Evanchan, M.R. Donnally, P. Binkley, and E. Mazzaferri Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction Clin Cardiol 33 2010 168 171
59. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
60. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
61. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
62. R.P. Kreutz, E.J. Stanek, and R. Aubert Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study Pharmacotherapy 30 2010 787 796
63. C.C. Huang, Y.-C. Chen, and H.-B. Leu Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention Am J Cardiol 105 2010 1705 1709
64. K.M. Stockl, L. Le, and A. Zakharyan Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor Arch Intern Med 170 2010 704 710
65. J.A. Rassen, N.K. Choudhry, J. Avorn, and S. Schneeweiss Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
66. W.A. Ray, K.T. Murray, and M.R. Griffin Outcomes with concurrent use of clopidogrel and proton-pump inhibitors Ann Intern Med 152 2010 337 345
67. M. Charlot, O. Ahlehoff, and M.L. Norgaard Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use Ann Intern Med 153 2010 378 386
68. C.S. Kwok, and Y.K. Loke Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Alimen Pharmacol Ther 31 2010 810 823
69. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 (*) loss-of-function allele or proton pump inhibitor coadministration J Am Coll Cardiol 56 2010 134 143
70. S.P. Dunn, T.E. Macaulay, and D.M. Brennan Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial (abstr) Circulation 118 Suppl 2 2008 S815
71. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
72. N.A. Farid, C.D. Payne, and D.S. Small Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently Clin Pharmacol Ther 81 2007 735 741 (Pubitemid 46625113)
73. J.W. Suh, B.K. Koo, and S.Y. Zhang Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 2006 1715 1722
74. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
75. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
76. D. Sibbing, N. von Beckerath, and T. Morath Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel Eur Heart J 31 2010 1205 1211
77. S.R. Steinhubl, J.J. Oh, and J.H. Oestreich Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 2008 527 534 (Pubitemid 351174272)
78. H.M. Judge, S.B. Patil, R.J. Buckland, J.A. Jakubowski, and R.F. Storey Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation following clopidogrel J Thromb Haem 8 2010 1820 1827
79. E.I. Lev, M.E. Arikan, and M. Vaduganathan Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease Am Heart J 154 2007 694.e17
80. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
81. K.P. Bliden, J. DiChiara, and L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
82. N.R. Desai, J.L. Mega, S. Jiang, C.P. Cannon, and M.S. Sabatine Interaction between cigarette smoking and clinical benefit of clopidogrel J Am Coll Cardiol 53 2009 1273 1278
83. J.S. Berger, D.L. Bhatt, and S.R. Steinhubl Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 120 2009 2337 2344
84. G. Gajos, P. Rostoff, A. Undas, and W. Piwowarska Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study J Am Coll Cardiol 55 2010 1671 1678
85. W.C. Lau, T.D. Welch, T. Shields, M. Rubenfire, U.S. Tantry, and P.A. Gurbel The Effect of St. John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP 3A4 metabolic activity J Cardiovasc Pharmacol 57 2011 86 93
86. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
87. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
88. A.M. Harmsze, J.W. van Werkum, and J.M. ten Berg CYP2C19 (*)2 and CYP2C9 (*)3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053
89. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
90. The CURE Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
91. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
92. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use J Am Coll Cardiol 56 2010 2051 2066